Evidence map›Paper›PMID 36865128›Full record

ArticlebioRxiv : the preprint server for biology2023

Multi-omic screening of invasive GBM cells in engineered biomaterials and patient biopsies reveals targetable transsulfuration pathway alterations.

Joseph H Garcia, Erin A Akins, Saket Jain, Kayla J Wolf, Jason Zhang, Nikita Choudhary, Meeki Lad, Poojan Shukla, Sabraj Gill, Will Carson and 4 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Joseph H GarciaDepartment of Neurosurgery; University of California San Francisco (UCSF).
Erin A AkinsDepartment of Bioengineering; Stanley Hall; University of California, Berkeley (UC Berkeley), Berkeley, CA 94720.
Saket JainDepartment of Neurosurgery; University of California San Francisco (UCSF).
Kayla J WolfDepartment of Bioengineering; Stanley Hall; University of California, Berkeley (UC Berkeley), Berkeley, CA 94720.
Jason ZhangDepartment of Bioengineering; Stanley Hall; University of California, Berkeley (UC Berkeley), Berkeley, CA 94720.
Nikita ChoudharyDepartment of Neurosurgery; University of California San Francisco (UCSF).
Meeki LadDepartment of Neurosurgery; University of California San Francisco (UCSF).
Poojan ShuklaDepartment of Neurosurgery; University of California San Francisco (UCSF).
Sabraj GillDepartment of Neurosurgery; University of California San Francisco (UCSF).
Will CarsonDepartment of Neurosurgery; University of California San Francisco (UCSF).
Luis CaretteDepartment of Neurosurgery; University of California San Francisco (UCSF).
Allison ZhengDepartment of Neurosurgery; University of California San Francisco (UCSF).
Sanjay KumarDepartment of Bioengineering; Stanley Hall; University of California, Berkeley (UC Berkeley), Berkeley, CA 94720.
Manish K AghiDepartment of Neurosurgery; University of California San Francisco (UCSF).
University of California, San Francisco · USStanley Foundation · USBerkeley College · USQB3 · US

Funding

Tumor cell and microenvironment changes causing antiangiogenic therapy resistanceR01NS079697 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2013 to 2021
$3.2M
Biophysical Control of Cell Form and Function by Single Actomyosin Stress Fibers: Instrument SupplementR01GM122375 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI KUMAR, SANJAY · 2017 to 2025
$2.7M
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systemsR01CA227136 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGHI, MANISH · 2018 to 2022
$2.2M
Retroviral RLI immunomodulatory gene therapy for glioblastomaR01NS123808 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Manish Aghi · 2022 to 2026
$2.1M
Mechanisms of adhesion and invasion in hyaluronic acid matricesR01CA260443 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI KUMAR, SANJAY · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA227136NCI NIH HHS R01 CA260443NIGMS NIH HHS R01 GM122375NINDS NIH HHS R01 NS079697NINDS NIH HHS R01 NS123808
6 · The paper itself

Abstract

While the poor prognosis of glioblastoma arises from the invasion of a subset of tumor cells, little is known of the metabolic alterations within these cells that fuel invasion. We integrated spatially addressable hydrogel biomaterial platforms, patient site-directed biopsies, and multi-omics analyses to define metabolic drivers of invasive glioblastoma cells. Metabolomics and lipidomics revealed elevations in the redox buffers cystathionine, hexosylceramides, and glucosyl ceramides in the invasive front of both hydrogel-cultured tumors and patient site-directed biopsies, with immunofluorescence indicating elevated reactive oxygen species (ROS) markers in invasive cells. Transcriptomics confirmed upregulation of ROS-producing and response genes at the invasive front in both hydrogel models and patient tumors. Amongst oncologic ROS, hydrogen peroxide specifically promoted glioblastoma invasion in 3D hydrogel spheroid cultures. A CRISPR metabolic gene screen revealed cystathionine gamma lyase (CTH), which converts cystathionine to the non-essential amino acid cysteine in the transsulfuration pathway, to be essential for glioblastoma invasion. Correspondingly, supplementing CTH knockdown cells with exogenous cysteine rescued invasion. Pharmacologic CTH inhibition suppressed glioblastoma invasion, while CTH knockdown slowed glioblastoma invasion

Indexed as

CRISPRGlioblastomaHydrogelsInvasionMetabolism

Identifiers

PMID36865128
PMCPMC9980149
OpenAlexW4321786255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.